Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: KAKALAK who wrote (4728)	1/16/2000 7:29:00 PM
From: Kingfisher	Read Replies (1) \| Respond to of 4891

Well, the flu keeps spreading and the FDA continues to keep us from a medication that could really help in the present situation that is nearing epidemic proportions. Just to refresh your memories I decided to post from the archives a statement made back in 1960 by Dr. Ralph Thompson who did not own any ADVR stock [because ADVR did not exist back then] and who was just honestly reporting an experience he had using Reticulose as a treatment for the flu. At a clinical symposium on viral diseases held in Miami Beach, Fla., on September 1, 1960, a retired colonel in the U.S. Medical Corps. spoke to the gathering of his early experiences with an anti-viral drug called Reticulose. Recalling that he was introduced to the drug during the early days of World War II by its inventor, Dr. Vincent LaPenta, as LaPenta administered the drug to several laboratory technicians who had become ill with influenza, Dr. Ralph Thompson said: "I shall never forget the miraculous course that followed the treatment with this drug and well remember those others of my command who became ill and stricken with influenza, who did not receive Reticulose therapy. They were actually ill; ill and incapacitated from 7 to 10 days. Yes, of cause, this is anecdotal but it was said by a former colonel in the U.S. Medical Corps. who had no conflict of interest. Why should the FDA dismiss his experience just because the evidence is anecdotal in nature and not backed by scientific/medical data?